Travis
Jackson

Travis has counseled numerous academic medical centers, health systems, hospitals and other providers in undertaking significant projects for their communities, such as :

• Pursuing mergers and acquisitions that enable hospitals to develop the economies of scale necessary to succeed under federal health reform and ensure the continuity of care in their communities
• Structuring joint venture relationships with physicians, hospitals or other providers that foster greater diversity in healthcare services
• Developing and implementing physician integration strategies that align hospital and physician incentives for high quality, cost-effective care
• Negotiating affiliation agreements that allow academic medical centers and health systems to increase their brand recognition through specialty service arrangements with community hospitals

Travis brings to his transactional work deep experience in the tax needs of nonprofit healthcare organizations.  He has worked with nonprofit healthcare organizations to navigate federal and state tax issues that affect their financial and operational needs, including:

• Structuring relationships that comply with IRS rules governing excess benefit transactions, private inurement and private benefit
• Establishing good corporate governance practices
• Creating for-profit subsidiaries
• Developing financial assistance policies, emergency medical care policies and billing and collection policies to comply with Section 501(r)
• Responding to audits and other investigations from the IRS and state tax authorities

As a result of his transactional work, Travis has substantial knowledge of the 340B Federal Drug Pricing Program. He has worked with clients to understand the obligations and opportunities that the 340B Federal Drug Pricing Program presents and has defended clients in HRSA and manufacturer investigations.

Travis served as the vice chair for the Tax and Finance Practice Group of the American Health Lawyers Association, and he has given numerous presentations and written extensively on healthcare transaction trends, federal tax issues, the 340B Federal Drug Pricing Program and corporate governance.